This calculation varies slightly for complex business models, but the underlying principle remains the same – multiplying the volume of output by the price or rate charged. Revenue is a key indi ...

ImmunityBio achieved a 55% disease-free rate at 12 months for BCG-unresponsive NMIBC and plans an sBLA submission in 2025. NSCLC Phase 2b trial (N=86) showed a median overall survival of 14.1 ...

And to make matters worse, when we calculate the implied annual procedure volume based on Procept’s market assumptions and system sales, we find it generates figures 75% - 110% above Procept’s ...

EBITDA stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It is a financial metric that represents the operational profitability of a company. EBITDA essentially answers ...

Johnson & Johnson has initiated an application seeking Food and Drug Administration approval of its TAR-200 drug-device combination for the treatment of certain patients with bladder cancer.

Interstitial cystitis (IC) and overactive bladder (OAB) are two distinct but related conditions that affect the bladder and can significantly affect quality of life. IC is also referred to as ...

If bacteria enter your urethra and your immune system does not fight them off, they may spread to your bladder and kidneys, resulting in a UTI. According to older research cited in a 2015 review ...

Pfizer said a late-stage study of its sasanlimab drug candidate met its key goal in certain patients with bladder cancer. Pfizer on Friday said the pivotal Phase 3 study evaluating sasanlimab in ...

Pfizer's Phase 3 trial showed sasanlimab with BCG improved event-free survival in high-risk NMIBC patients. Sasanlimab's safety profile aligns with known PD-1 inhibitors and BCG data from previous ...